News Release

Presentation of 1-year IVAN and 2-year CATT study results

Special session at the 2012 ARVO Annual Meeting

Peer-Reviewed Publication

Association for Research in Vision and Ophthalmology

Rockville, Md.: ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

These two multicenter randomized clinical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Eye Institute, respectively, evaluate the relative efficacy and safety of Lucentis and Avastin in the management of neovascular age-related macular degeneration (AMD).

The presentation will also live-streamed at http://prolibraries.com/arvo/registration/event. While annual meeting registration is required for the session in Fort Lauderdale, the online is event is free.

The 2012 ARVO Annual Meeting, Translational Research: Seeing the Possibilities, takes place May 6 – 10 in Fort Lauderdale, Fla. Registration information can be found at www.arvo.org/am.

###

The Association for Research and Vision in Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

Visit us at:

Website:
www.arvo.org

Twitter:
www.twitter.com/#!/ARVOinfo

Facebook:
www.facebook.com/ARVOinfo

Flicker:
www.flickr.com/photos/ARVOinfo

YouTube:
www.youtube.com/user/ARVOinfo


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.